CytRx rallies after conference presentation

|About: CytRx Corporation (CYTR)|By:, SA News Editor

CytRx (CYTR) trades 6% higher in premarket action.

Investors seem pleased with Tuesday's presentation at the LD MICRO Main Event Conference in L.A.

The company discussed aldoxorubicin, reviewed some data from on-going Phase 2 trials, and talked a bit about the upcoming Phase 3 study (Q1 2014 is planned start).

CYTR also presented a timeline, outlining "numerous upcoming catalysts."

Those interested can view the full presentation here.